BREAKING: Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, today announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence from COVID-19 infection and mRNA vaccinations, linked to genomic instability, integration events, aggressive cancers, disabilities, and multi-system injuries. This work represents a formal research collaboration between Neo7Bioscience and Dr. Peter A. McCullough, M.D., M.P.H., Nicolas Hulscher, M.P.H., and the McCullough Foundation. Scholars from both Neo7Bioscience and the McCullough Foundation worked in unison to deliver high-quality peer-reviewed analyses of real patient cases, combining advanced multi-omic surveillance with rigorous clinical and pathological evaluation.

Key Referenced Studies

• Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination – World Journal of Experimental Medicine (https://pmc.ncbi.nlm.nih.gov/articles/PMC12767256/)
• Persistence of Vaccine mRNA, Plasmid DNA, Spike Protein, and Genomic Dysregulation Over 3.5 Years Post-COVID-19 mRNA Vaccination – Medical Research Archives (https://esmed.org/MRA/mra/article/view/7631)
• Genomic Integration and Molecular Dysregulation in Aggressive Stage IV Bladder Cancer Following COVID-19 mRNA Vaccination by John A. Catanzaro, Nicolas Hulscher, Peter A. McCullough – International Journal of Innovative Research in Medical Science (https://ijirms.in/index.php/ijirms/article/view/2130, October 2025)
• Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis by Nicolas Hulscher et al. – ESC Heart Failure (https://pubmed.ncbi.nlm.nih.gov/38221509/)
• Gene Expression Alterations Induced by mRNA Vaccines by Nicolas Hulscher, M.P.H., Peter A. McCullough, M.D., M.P.H., John A. Catanzaro, N.D., Ph.D. – Journal of the American Physicians and Surgeons (https://jpands.org/vol31no1/hulscher.pdf)

These collaborative studies document vaccine-derived mRNA, plasmid DNA (with SV40 elements), and bioactive Spike protein persisting beyond 3.5 years; coordinated transcriptomic and proteomic reprogramming; the first reported genomic integration of Spike sequences in a human patient with rapidly progressive stage IV bladder cancer; and strong causal associations in fatal myocarditis cases. The joint scholarly effort between Neo7Bioscience and McCullough Foundation researchers has enabled the rigorous peer-reviewed examination of real-world patient data at the intersection of molecular surveillance and clinical pathology.

Neo7Bioscience’s Spike X Detect Molecular Surveillance Panel and HealthIndex Reports are powered by the company’s proprietary aHI-PBIMA® platform—an augmented hybrid intelligence system unique to Neo7Bioscience. This platform identifies REViSS transcriptional/translational instabilities and designs patient-specific ITI-PES precision peptides that intercept dysregulated gene–protein pathways, delivering measurable clinical recovery.

Transformative Case Study Reviews (Anonymized)

Case Profile 1 (Spike X Detect Panel): The patient presented with unfavorable regulation in oxidative stress and mitochondrial dysfunction (elevated BAX driving apoptosis; reduced GPX4 impairing antioxidant defense), neuroinflammation (IFNAR2 upregulation), and gut-barrier disruption (APC downregulation), contributing to cardiac dysrhythmias and systemic decline. Overall TTIS indicated a pathogenic shift. Personalized peptides restored mitochondrial stability, improved redox balance, tempered interferon signaling, and reinforced epithelial integrity—resulting in resolution of dysrhythmias, reduced fatigue, and markedly enhanced daily function and resilience.

Case Profile 2 (HealthIndex Spike X Detect): Extensive hallmark dysregulation spanned persistent neuroinflammation, oxidative stress/mitochondrial dysfunction, immune imbalance, endothelial injury, microbiota disruption, and genomic instability. Customized ITI-PES sequences, including mutation-resilient Spike mitigation and targeted edits (e.g., CX3CR1, SIRT3, TLR4, LMNA), directly addressed these drivers. The patient, previously limited by debilitating chronic symptoms, experienced progressive resolution of brain fog, fatigue, autonomic dysfunction, and pain, regaining mobility, cognitive clarity, and quality of life.

Case Profile 3 (Hypertension, Hypothyroid, Cerebral Aneurysm mRNA Complications): Multi-hallmark involvement included vascular remodeling, endothelial dysfunction, pro-inflammatory cascades, sympathetic dysregulation, and thyroid hormone disruption. Primary and revised secondary ITI-PES designs targeted critical nodes (ACE, NRP1, LRP1, PDGFRB, PECAM1, and others with cell-penetrating modifications). The patient achieved excellent blood pressure control, normalized thyroid function, vascular stabilization, and substantial reduction in aneurysm-related risks and symptoms, enabling return to active daily living.

Case Profile 4 (Spike X Detect Molecular Surveillance Panel): Profiling revealed hallmark-specific transcriptional instability across neuroinflammation, oxidative damage, immune and endothelial dysfunction, and related pathways. Implementation of tailored bivalent and Spike-mitigation precision peptides led to downregulation of pathogenic signals, resolution of key inflammatory and neurological symptoms, improved energy, and substantial recovery of physical endurance and cognitive function.

Case Profile 5 (Leukemia with Spike Protein Complication – Spike Mitigation Program): Following years of progressive decline after occupational pesticide exposure that preceded her leukemia diagnosis, the patient had undergone extensive conventional and integrative therapies, required more than seven blood transfusions, and experienced further clinical deterioration after additional spike protein exposure. Immediately prior to initiating the NEO7 Spike Mitigation Program, clinicians and staff observed profound jaundice, near-constant sleep, severe fatigue, and loss of functional capacity; she had begun preparations to close her medical practice. Within approximately 10 days of starting the program, she reported a marked restoration of energy, stamina, and overall well-being, enabling her to dress for and attend a formal wedding for the first time in years. Although serial laboratory studies continue to reflect underlying hematologic abnormalities consistent with leukemia—including anemia, thrombocytopenia, and leukocytosis—metabolic parameters have shown stability, providing an objective baseline for continued longitudinal monitoring as recovery progresses.

John A. Catanzaro, CEO, Co-Founder, and Chief Vision and Innovation Officer of Neo7Bioscience, stated: “The convergence of persistent Spike protein, gene-expression chaos, genomic integration, and multi-system injury demands precise molecular intervention. Through our collaborative research partnership with Dr. Peter A. McCullough, M.D., M.P.H., Nicolas Hulscher, M.P.H., and the McCullough Foundation, Neo7Bioscience and McCullough Foundation scholars have worked in unison to produce high-quality peer-reviewed analyses of real patient cases. Our proprietary aHI-PBIMA® platform—unique to Neo7Bioscience—maps these disruptions and counters them with individualized peptides, enabling patients who had exhausted conventional options to regain function and hope. We remain committed to expanding access to these solutions under rigorous ethical and regulatory standards.”

Neo7Bioscience continues advancing computational models, hybrid intelligence frameworks, and strategic partnerships—including ongoing collaboration with the McCullough Foundation—to scale precision interventions for complex post-infection and post-vaccination sequelae.

About Neo7Bioscience

Neo7Bioscience pioneers personalized precision medicine through multi-omics surveillance, its proprietary augmented hybrid intelligence (aHI) technology, and proprietary peptide design for cancer, autoimmune and neurodegenerative conditions, post-viral and vaccine-related injuries, and longevity applications. For more information, visit https://neo7bioscience.com/contactus